Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 1 | BMC Infectious Diseases

Figure 1

From: Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients

Figure 1

CMV treatment with valganciclovir in patients 1-6. valganciclovir dosage (red rectangle), ganciclovir plasma concentration (closed white circle: concentration measured at trough, closed white triangle: concentration measured 3 h after last dose, red line: concentration predicted by population pharmacokinetic model), CMV viremia (blue square and solid blue line) and symptoms period (blue diamond)

Back to article page